The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual Fund

Fii Holding DeclinedOwnership Changes View source PDF Explain this filing

GLAND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.9%Reaction day

₹1955.00

prior close

₹1939.30

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-1.3%+0.3% vs market

Pharmaceuticals peers, median of 147sector-0.8%-0.1% vs sector

On the reaction day the stock moved 0.3 pts more than Nifty Smallcap 250 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

-0.1

15m

-0.1

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.9-1.3+0.3-0.8-0.1

Next day

-0.9-0.8-0.1-0.6-0.3

-1.0-0.8-0.2-0.3-0.8

-0.0-0.2+0.1-0.6+0.6

+1.1-0.6+1.6-0.6+1.7

+0.8+0.7+0.0-0.9+1.7

-0.5+1.9-2.3-0.0-0.5

15d

-4.7+0.5-5.2-0.8-3.9

-4.3+1.1-5.4-1.0-3.4

+0.2+1.2-1.1-1.3+1.5

-3.6+1.6-5.2-4.7+1.1

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

ICICI Prudential Mutual Fund has informed the stock exchanges that it sold 33,44,886 equity shares (2.03% of paid-up capital) of Gland Pharma Ltd through the secondary market between April 12, 2025 and August 06, 2025. As a result, its holding in the company declined from 83,71,114 shares (5.08%) to 50,26,228 shares (3.05%). The fund clarified that the shares are held purely from an investment perspective and not with any intention to seek control. The total equity share capital of Gland Pharma stands at 16,47,56,423 shares of face value Re. 1 each.

Likely market impact

This is a notable reduction by a large institutional investor, which could exert mild short-term selling pressure on the stock. However, the holding remains meaningful at 3.05%, suggesting the fund has not completely exited the stock.